NASDAQ:PPD PPD (PPD) Stock Price, News & Analysis → Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad) Free PPD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.28▼$47.2850-Day Range$47.10▼$47.4152-Week Range$31.54▼$47.41VolumeN/AAverage Volume1.91 million shsMarket Capitalization$16.61 billionP/E Ratio47.28Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PPD alerts: Email Address Ad Paradigm PressBiden out June 13; Kamala won’t replace him?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About PPD Stock (NASDAQ:PPD)PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.Read More Ad Paradigm PressBiden out June 13; Kamala won’t replace him?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. PPD Stock News HeadlinesMay 2, 2024 | nj.comBoys Tennis: Results & links for Thursday, May 2May 1, 2024 | msn.comMan wounded in broad daylight shooting in PortsmouthMay 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.May 1, 2024 | msn.comGunfire incident reported in Peoria neighborhood hours after teen's fatal shootingMay 1, 2024 | msn.comPPD searching for missing, endangered man Alexander CookMay 1, 2024 | msn.comVermont H.S. scores, postponements for Tuesday, April 30: See how your favorite team faredApril 30, 2024 | msn.comUsing basketball to improve police-community relations and lower gun violenceApril 30, 2024 | msn.comDriver Robbed Of $40K While Fixing Flat Tire In Philadelphia: AuthoritiesMay 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 30, 2024 | seekingalpha.comThermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)April 29, 2024 | msn.comMore than 12 pounds of drugs seized, Palestine man arrestedApril 29, 2024 | msn.comPhilly officer reinstated 18 months after judge drops murder charges against himApril 28, 2024 | msn.comPortsmouth police chief condemns deadly shooting of 10-year-old boyApril 28, 2024 | msn.comFamily to hold vigil for 10-year-old killed in PortsmouthApril 28, 2024 | msn.comWeekend violence leaves 4 injured across PhiladelphiaApril 28, 2024 | msn.comHit-and-run in Philadelphia leaves man hospitalized with serious injuries, police sayApril 27, 2024 | msn.comPPD: Boy shot to death on Farragut StreetApril 27, 2024 | msn.comPortsmouth police chief condemns deadly shooting of young boyApril 27, 2024 | msn.comPhoenix police internal investigations 'not thorough' enough, watchdog reports showApril 26, 2024 | markets.businessinsider.comSAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor SetbacksApril 26, 2024 | msn.comDetails Emerge In PPD Shooting Of Maurice SamuelsApril 26, 2024 | msn.comPhiladelphia Police Officer Return to PPD After Dismissed Murder ChargesApril 26, 2024 | msn.comBrave four-year-old awarded 911 Hero AwardApril 26, 2024 | msn.comUPDATE: Val U Stay closed by city due to living conditionsApril 26, 2024 | msn.comPacifica police look for person of interest in arson investigationApril 26, 2024 | yahoo.comPPD: Help identify people in video near crime sceneApril 24, 2024 | pnj.comPensacola police warns of phone scams after resident taken for nearly $50,000See More Headlines Receive PPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial Physical Research Sub-IndustryN/A Current SymbolNASDAQ:PPD CUSIPN/A CIK1793294 Webwww.ppdi.com Phone910-251-0081FaxN/AEmployees26,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.00 Trailing P/E Ratio47.28 Forward P/E Ratio32.16 P/E Growth2.11Net Income$153.69 million Net Margins6.11% Pretax Margin7.31% Return on Equity-89.48% Return on Assets7.94% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual Sales$4.68 billion Price / Sales3.55 Cash Flow$1.99 per share Price / Cash Flow23.71 Book Value($1.21) per share Price / Book-39.07Miscellaneous Outstanding Shares351,395,000Free Float344,718,000Market Cap$16.61 billion OptionableNot Optionable Beta1.96 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. David S. Simmons (Age 56)Chairman & CEO Comp: $3.42MMr. Christopher G. Scully (Age 50)Exec. VP, CFO, Treasurer & Assistant Sec. Comp: $1MMr. William J. Sharbaugh (Age 58)Chief Operating Officer Comp: $1.12MMr. Anshul Thakral (Age 43)Exec. VP, Chief Commercial Officer & Pres of Evidera Comp: $1.13MDr. David Michael Johnston (Age 52)Exec. VP of Global Clinical Devel. Comp: $788.87kMr. Glen Donovan (Age 47)Chief Accounting Officer Mr. B. Judd Hartman (Age 57)Exec. VP & Chief Admin. Officer Ms. Tracy H. Krumme (Age 53)VP & Head of Investor Relations Ms. Julia James (Age 46)Exec. VP, Gen. Counsel & Sec. Mr. Ronald E. Garrow (Age 57)Exec. VP & Chief HR Officer More ExecutivesKey CompetitorsMedpaceNASDAQ:MEDPCharles River Laboratories InternationalNYSE:CRLIncyteNASDAQ:INCYPRA Health SciencesNASDAQ:PRAHICON PublicNASDAQ:ICLRView All Competitors Should I Buy PPD Stock? PPD Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in PPD, Inc.: PPD, Inc. has a strong presence in the biopharmaceutical industry worldwide, offering a wide range of drug development services. David Johnston, Ph.D., the executive vice president and global head of clinical development services at PPD, brings extensive experience and expertise to the company. PPD's Accelerated Enrollment Solutions (AES) business provides data-driven patient recruitment for clinical trials, enhancing efficiency and speed in trial execution. Recent collaborations and partnerships, such as the one with Science 37 for digital trials, demonstrate PPD's commitment to innovation and staying at the forefront of industry trends. Considering the current stock price and market trends, PPD, Inc. shows potential for growth and value appreciation. Cons Investors should be bearish about investing in PPD, Inc. for these reasons: Market volatility and regulatory challenges in the biopharmaceutical industry can impact PPD's operations and financial performance. Dependency on external factors such as government regulations, clinical trial outcomes, and industry competition may pose risks to investment returns. Fluctuations in global economic conditions and healthcare spending could affect the demand for PPD's services and solutions. Uncertainties related to the success of new drug developments and clinical trials could influence the company's revenue streams and profitability. Investors need to carefully assess the competitive landscape and potential threats to PPD's market position to make informed investment decisions. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these PPD pros and cons to contact@marketbeat.com. PPD Stock Analysis - Frequently Asked Questions How were PPD's earnings last quarter? PPD, Inc. (NASDAQ:PPD) posted its quarterly earnings data on Wednesday, October, 27th. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.05. The business earned $1.56 billion during the quarter, compared to the consensus estimate of $1.41 billion. PPD had a negative trailing twelve-month return on equity of 89.48% and a net margin of 6.11%. PPD's quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.15 earnings per share. What other stocks do shareholders of PPD own? Based on aggregate information from My MarketBeat watchlists, some companies that other PPD investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Johnson & Johnson (JNJ), Salesforce (CRM), Pfizer (PFE), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), RTX (RTX) and Verizon Communications (VZ). When did PPD IPO? PPD (PPD) raised $1.5 billion in an IPO on Thursday, February 6th 2020. The company issued 60,000,000 shares at a price of $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair acted as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers. This page (NASDAQ:PPD) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PPD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.